Jul. 29 at 5:11 PM
$PYPD Regulatory Triumph
Accelerated FDA Approval Path: The FDA has officially accepted the New Drug Application (NDA) for D-PLEX100 under an elite Priority Review status.Beating Expectations:
The FDA assigned a rapid November 28, 2026 PDUFA target action date. This positions the company a full quarter ahead of previous Wall Street timelines.
Validating Critical Medical Need: Earning Priority Review—backed by Breakthrough, Fast Track, and QIDP designations—firmly validates the immense clinical value and market urgency for PolyPid's surgical infection solution.
Immediate Multi-Million Inflow: NDA acceptance immediately unlocks a
$15 million milestone payment securing a powerful
$30 million total in recent upfront capital.
Formidable Cash Runway: This cash injection boosts pro forma cash to a robust ~
$41 million, completely eliminating near-term financing risks and funding operations comfortably into 2027.
